Clinical Trial Update: Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating Naxitamab for high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage therapy; curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Naxitamab (naxitamab)

Snippet

Sponsor: Y-mAbs Therapeutics | Conditions: Neuroblastoma | Phase 2 | Status: RECRUITING